Girgenti, Matthew J. http://orcid.org/0000-0003-1647-326X
,
Wang, Jiawei http://orcid.org/0000-0003-2627-4897
Ji, Dingjue http://orcid.org/0000-0001-6288-8891
Cruz, Dianne A.
Stein, Murray B. http://orcid.org/0000-0001-9564-2871
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Young, Keith A.
Huber, Bertrand R.
Williamson, Douglas E.
Friedman, Matthew J. http://orcid.org/0000-0002-0497-6890
Krystal, John H. http://orcid.org/0000-0001-6952-1726
Zhao, Hongyu http://orcid.org/0000-0003-1195-9607
Duman, Ronald S. http://orcid.org/0000-0001-8690-8439
Funding for this research was provided by:
Brain and Behavior Research Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH093897, MH105910)
Article History
Received: 26 March 2020
Accepted: 26 October 2020
First Online: 21 December 2020
Competing interests
: J.G. is named as a co-inventor on PCT patent application number 15/878,640 entitled “Genotype-guided dosing of opioid agonists”, filed 24 January 2018. M.B.S. has in the past 3 years been a consultant for Aptinyx, Bionomics, EpiVario, Greenwich Biosciences, Janssen, and Jazz Pharmaceuticals. He also receives payment from the following entities for editorial work: <i>Biological Psychiatry</i> (published by Elsevier), <i>Depression and Anxiety</i> (published by Wiley) and <i>UpToDate</i>. J.H.K. has consulting agreements (less than US$10,000 per year) with the following: AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics, Limited (Australia), Boehringer Ingelheim International, COMPASS Pathways, Limited, United Kingdom, Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc., Heptares Therapeutics, Limited (UK), Janssen Research & Development, Otsuka America, Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries and Taisho Pharmaceutical Co., Ltd. J.H.K. serves on the scientific advisory boards of Bioasis Technologies, Inc., Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), BlackThorn Therapeutics, Inc., Cadent Therapeutics (Clinical Advisory Board), Cerevel Therapeutics, LLC., EpiVario, Inc., Lohocla Research Corporation, PsychoGenics, Inc.; is on the board of directors of Inheris Biopharma, Inc.; has stock options with Biohaven Pharmaceuticals Medical Sciences, BlackThorn Therapeutics, Inc., EpiVario, Inc. and Terran Life Sciences; and is editor of <i>Biological Psychiatry</i> with income greater than $10,000. R.S.D. has received consulting fees from Taisho, Johnson & Johnson and Naurex; and receives grant support from Taisho, Johnson & Johnson, Naurex, Navitor, Allergan, Lundbeck and Lilly. None of the above listed companies or funding agencies had any influence on the content of this article.